Evaluating prescriber preferences for the treatment of indeterminate Chagas disease (EPPIC study): an international survey
The EPPIC study reveals that while a 70% efficacy threshold is a critical inflection point for prescriber willingness to adopt new Chagas disease treatments, factors such as improved safety, prevention of mother-to-child transmission, and greater accessibility are equally vital in shaping prescribing preferences for regimens with moderate efficacy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Chagas disease is a persistent infection caused by a microscopic parasite that lives in the blood. It affects millions of people, primarily in Latin America, and can lead to severe heart problems if left untreated. For decades, the medical community has relied on just two drugs to fight this infection. While these medicines work, they are difficult for patients to stick with. The treatment courses are long, often lasting two months, and the drugs frequently cause unpleasant side effects that make people stop taking them before they are cured. Because so many patients drop out, the infection often remains in their bodies, continuing to damage their health. Scientists have been exploring whether shorter treatments or lower doses could work just as well without the harsh side effects, but a critical question remained unanswered: how much effectiveness would doctors be willing to trade for a safer, easier treatment?
To answer this, a team of researchers conducted a survey to ask the people who actually prescribe these medicines what they would accept. They reached out to doctors, nurses, and public health experts who have experience treating Chagas disease in both the countries where the disease is common and those where it is not. The goal was not to test a new drug in a lab, but to understand the mindset of the healthcare providers. The researchers wanted to know the lowest level of cure rate that a doctor would still feel comfortable prescribing, especially if the new option offered fewer side effects or was easier to get. They presented these experts with hypothetical scenarios involving new treatments that were slightly less effective than the current standard but offered other benefits, such as preventing the disease from passing from a mother to her baby or being available more easily in remote areas.
The results of the survey revealed a clear tipping point in how these professionals view treatment. When the researchers asked if they would prescribe a new regimen that cured the infection in seventy to seventy-nine percent of cases, nearly half of the respondents said they would likely or very likely do so. However, as the imagined cure rate dropped below this level, the willingness to prescribe fell sharply. When the effectiveness was imagined to be between sixty and sixty-nine percent, only about one in five doctors said they would prescribe it. If the cure rate dropped even further to between fifty and fifty-nine percent, the number of willing prescribers shrank to a tiny fraction. This suggests that for these experts, a cure rate of seventy percent acts as a critical boundary; below this line, the treatment is no longer seen as a viable option, regardless of other benefits.
Despite this firm line in the sand, the study showed that doctors are not rigid. They are willing to consider treatments with moderate effectiveness if those treatments solve other major problems. The survey found that the desire to prevent the disease from being passed from mother to child, the promise of fewer and milder side effects, and the ability to use the drug as a backup option all increased the willingness to prescribe a less effective regimen. For the very lowest effectiveness levels, the simple fact that the medicine would be easier to obtain became a deciding factor. The participants also highlighted that the current drugs are often hard to get and that the long treatment time is a major hurdle. They noted that while the current medicines are effective, the high rate of side effects and the difficulty in monitoring whether the treatment worked are significant barriers to care.
The researchers concluded that the decision to use a new medicine is not based on a single number but on a balance of risks and benefits. A treatment does not need to be perfect to be useful, but it must meet a minimum standard of effectiveness to be trusted. The study suggests that future medical trials should aim for a cure rate of at least seventy percent to be considered acceptable by the medical community. If a new treatment can reach that threshold while also offering a shorter course, fewer side effects, or better access, it has a strong chance of being adopted. This approach could help bridge the gap between scientific possibility and real-world practice, ensuring that more people with Chagas disease can complete their treatment and recover fully.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.